See more : Mohota Industries Limited (MOHOTAIND.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Concert Pharmaceuticals, Inc. (CNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concert Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Swire Pacific Limited (SWRBY) Income Statement Analysis – Financial Results
- Nippon Kayaku Co., Ltd. (4272.T) Income Statement Analysis – Financial Results
- Goldquest Mining Corp. (GQC.V) Income Statement Analysis – Financial Results
- TC Traders Club S.A. (TRAD3.SA) Income Statement Analysis – Financial Results
- SiS International Holdings Limited (0529.HK) Income Statement Analysis – Financial Results
Concert Pharmaceuticals, Inc. (CNCE)
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 87.56M | 61.62M | 59.82M | 43.15M | 30.22M | 36.98M | 28.89M | 27.47M | 21.79M | 24.19M | 23.44M |
| General & Administrative | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Other Expenses | 283.00K | 301.00K | 306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.90M | 12.84M | 0.00 | 0.00 |
| Operating Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Cost & Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | -127.00K | 815.00K | 447.00K | 309.00K | 1.15M | 1.67M | 1.86M | 18.00K |
| Depreciation & Amortization | 4.02M | 3.81M | 827.00K | 1.25M | 1.01M | 893.00K | 785.00K | 1.05M | 1.35M | 1.45M | 1.62M |
| EBITDA | -73.49M | -68.84M | -78.19M | -54.46M | 97.16M | -49.83M | 25.70M | -29.50M | -3.04M | -17.14M | -9.68M |
| EBITDA Ratio | -225.57% | -871.15% | -7,259.80% | -518.46% | 67.52% | -28,636.21% | 38.51% | -343.95% | -11.98% | -133.36% | -49.74% |
| Operating Income | -77.51M | -72.65M | -79.02M | -55.58M | 92.65M | -51.17M | 24.79M | -30.60M | -4.41M | -18.61M | -11.35M |
| Operating Income Ratio | -237.92% | -919.35% | -7,336.58% | -529.12% | 64.39% | -29,406.32% | 37.15% | -356.79% | -17.36% | -144.84% | -58.28% |
| Total Other Income/Expenses | -2.54M | -2.20M | 849.00K | -127.00K | 2.69M | 447.00K | -185.00K | -1.10M | -1.65M | -1.83M | 26.00K |
| Income Before Tax | -80.05M | -74.85M | -78.17M | -55.71M | 95.34M | -50.72M | 24.60M | -31.70M | -6.06M | -20.44M | -11.32M |
| Income Before Tax Ratio | -245.72% | -947.24% | -7,257.75% | -530.33% | 66.26% | -29,149.43% | 36.87% | -369.62% | -23.84% | -159.11% | -58.15% |
| Income Tax Expense | 2.54M | -85.00K | -837.00K | 313.00K | -300.00K | 447.00K | 429.00K | 49.00K | 21.00K | 22.00K | 44.00K |
| Net Income | -82.59M | -74.77M | -77.33M | -56.02M | 95.64M | -50.72M | 24.17M | -31.70M | -6.06M | -20.44M | -11.32M |
| Net Income Ratio | -253.53% | -946.17% | -7,180.04% | -533.31% | 66.47% | -29,149.43% | 36.23% | -369.62% | -23.84% | -159.11% | -58.15% |
| EPS | -2.40 | -2.40 | -3.26 | -2.40 | 4.22 | -2.28 | 1.14 | -2.00 | -0.35 | -1.82 | -1.01 |
| EPS Diluted | -2.40 | -2.40 | -3.26 | -2.40 | 4.08 | -2.28 | 1.09 | -2.00 | -0.35 | -1.82 | -1.01 |
| Weighted Avg Shares Out | 34.41M | 31.20M | 23.74M | 23.37M | 22.64M | 22.23M | 21.15M | 15.84M | 17.22M | 11.21M | 11.21M |
| Weighted Avg Shares Out (Dil) | 34.41M | 31.20M | 23.74M | 23.37M | 23.44M | 22.23M | 22.27M | 15.84M | 17.22M | 11.21M | 11.21M |
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's on-demand fireside chat at the Jefferies London conference will be available beginning at 8:00 a.m. GMT on November 18, 2021.
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2021 Results - Earnings Call Transcript
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2021 Results - Earnings Call Transcript
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates
Concert (CNCE) delivered earnings and revenue surprises of -2.63% and 117.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the third quarter of 2021.
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2021. “The CTP-543 pivotal program is progressing on track to support an NDA filing with the FDA in early 2023,” said Roger Tung, Ph.D.,...
Are These Trending Penny Stocks Worth Buying at Current Levels?
Check these trending penny stocks out for your watchlist The post Are These Trending Penny Stocks Worth Buying at Current Levels? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Concert Pharmaceuticals (CNCE) Stock: Why The Price Surged Today
The stock price of Concert Pharmaceuticals Inc (NASDAQ: CNCE) increased 27.43% today. This is why it happened.
Why These Penny Stocks Popped Today, 3 to Watch
Are these penny stocks on your November watchlist? The post Why These Penny Stocks Popped Today, 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Concert Pharmaceuticals Announces $65 Million Financing
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals entered into an agreement with BVF Partners and RA Capital to raise gross proceeds of $65 million.
Concert Pharmaceuticals Announces $65 Million Financing
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million. In addition, Concert will have the potential...
Source: https://incomestatements.info
Category: Stock Reports